106 related articles for article (PubMed ID: 2719046)
1. Pharmaceutical companies should offer reliable information, not freebies.
Hulstrand EP
Am J Hosp Pharm; 1989 Apr; 46(4):702. PubMed ID: 2719046
[No Abstract] [Full Text] [Related]
2. Internet strategies being implemented by pharmaceutical companies.
Goldstein D; Flory J
Med Interface; 1997 May; 10(5):48-50. PubMed ID: 10167503
[No Abstract] [Full Text] [Related]
3. For pharmaceutical companies, a data warehouse can be just what the doctor ordered.
Desai A
Health Manag Technol; 1999 Mar; 20(2):20-2. PubMed ID: 10346471
[No Abstract] [Full Text] [Related]
4. Emergency telephone numbers of pharmaceutical companies.
Larson RL
Hosp Pharm; 1983 Jul; 18(7):333-8. PubMed ID: 10299064
[No Abstract] [Full Text] [Related]
5. How to ask drug companies for help.
Hayes JD
Am J Nurs; 1993 Jan; 93(1):38-41. PubMed ID: 8447345
[No Abstract] [Full Text] [Related]
6. Regulating manufacturer-affiliated communication in the information age.
Schulman KA; Abernethy DR; Rathore SS; Woosley RL
Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
[No Abstract] [Full Text] [Related]
7. US drug industry bans expensive freebies for MDs, Canada raises fines.
Sibbald B
CMAJ; 2002 Sep; 167(5):522. PubMed ID: 12240824
[No Abstract] [Full Text] [Related]
8. The economic wisdom of regulating pharmaceutical "freebies".
Fisher SH
Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416
[No Abstract] [Full Text] [Related]
9. Information responsibilities of generic drug companies.
Cramer R
Am J Hosp Pharm; 1986 Jul; 43(7):1674, 1679. PubMed ID: 3752098
[No Abstract] [Full Text] [Related]
10. Redistribution of risk throughout the pharmaceutical industry.
Scheur BS
Med Interface; 1994 Oct; 7(10):77-80. PubMed ID: 10137569
[TBL] [Abstract][Full Text] [Related]
11. Bristol-Myers Squibb drug information department services.
Sylvan L; Palmer-Shevlin N
Hosp Pharm; 1995 Jan; 30(1):38-9, 44. PubMed ID: 10139729
[TBL] [Abstract][Full Text] [Related]
12. Drug information services at Eli Lilly and Company.
Pfeil-Doyle JL; Jones MD; Oberlin JA; Benitez J
Am J Hosp Pharm; 1990 Sep; 47(9):1996-8. PubMed ID: 2220850
[No Abstract] [Full Text] [Related]
13. A prescription for better prescriptions.
Woosley RL
Issues Sci Technol; 1994; 10(3):59-66. PubMed ID: 10133487
[No Abstract] [Full Text] [Related]
14. Report raises questions about drug companies advertising budgets.
AIDS Policy Law; 1999 Aug; 14(14):1, 6. PubMed ID: 11366996
[TBL] [Abstract][Full Text] [Related]
15. Quality of drug information service provided by pharmaceutical manufacturers.
Doyal LE
Am J Hosp Pharm; 1990 May; 47(5):1014. PubMed ID: 2337090
[No Abstract] [Full Text] [Related]
16. [Offer for better drug information].
Højgaard L
Ugeskr Laeger; 1994 Feb; 156(6):832-3. PubMed ID: 8016994
[No Abstract] [Full Text] [Related]
17. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical published literature databases: a survey.
Hull P
Med Ref Serv Q; 1996; 15(1):77-88. PubMed ID: 10157847
[TBL] [Abstract][Full Text] [Related]
19. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
Hamilton C; Lokuge B; Denniss R
Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919
[No Abstract] [Full Text] [Related]
20. Drug companies crying foul over Medicaid's formulary push.
Carroll J
Manag Care; 2002 Nov; 11(11):12-4. PubMed ID: 12491852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
